A citation-based method for searching scientific literature

H A Burris, M J Moore, J Andersen, M R Green, M L Rothenberg, M R Modiano, M C Cripps, R K Portenoy, A M Storniolo, P Tarassoff, R Nelson, F A Dorr, C D Stephens, D D Von Hoff. J Clin Oncol 1997
Times Cited: 4555







List of co-cited articles
563 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Daniel D Von Hoff, Thomas Ervin, Francis P Arena, E Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A Tjulandin, Wen Wee Ma, Mansoor N Saleh,[...]. N Engl J Med 2013
63

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Thierry Conroy, Françoise Desseigne, Marc Ychou, Olivier Bouché, Rosine Guimbaud, Yves Bécouarn, Antoine Adenis, Jean-Luc Raoul, Sophie Gourgou-Bourgade, Christelle de la Fouchardière,[...]. N Engl J Med 2011
56

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Malcolm J Moore, David Goldstein, John Hamm, Arie Figer, Joel R Hecht, Steven Gallinger, Heather J Au, Pawel Murawa, David Walde, Robert A Wolff,[...]. J Clin Oncol 2007
19

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, Yan-Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean F Blanc,[...]. Lancet 2016
603
18

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Thierry Conroy, Pascal Hammel, Mohamed Hebbar, Meher Ben Abdelghani, Alice C Wei, Jean-Luc Raoul, Laurence Choné, Eric Francois, Pascal Artru, James J Biagi,[...]. N Engl J Med 2018
18

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
952
16

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
12

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
11

Pancreatic cancer.
Jonathan D Mizrahi, Rishi Surana, Juan W Valle, Rachna T Shroff. Lancet 2020
655
10

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
10

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.
Lola Rahib, Benjamin D Smith, Rhonda Aizenberg, Allison B Rosenzweig, Julie M Fleshman, Lynn M Matrisian. Cancer Res 2014
9

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Kenneth P Olive, Michael A Jacobetz, Christian J Davidson, Aarthi Gopinathan, Dominick McIntyre, Davina Honess, Basetti Madhu, Mae A Goldgraben, Meredith E Caldwell, David Allard,[...]. Science 2009
9

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
936
8

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Helmut Oettle, Peter Neuhaus, Andreas Hochhaus, Jörg Thomas Hartmann, Klaus Gellert, Karsten Ridwelski, Marco Niedergethmann, Carl Zülke, Jörg Fahlke, Michael B Arning,[...]. JAMA 2013
8

The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.
Won Jin Ho, Elizabeth M Jaffee, Lei Zheng. Nat Rev Clin Oncol 2020
287
8

Genomic analyses identify molecular subtypes of pancreatic cancer.
Peter Bailey, David K Chang, Katia Nones, Amber L Johns, Ann-Marie Patch, Marie-Claude Gingras, David K Miller, Angelika N Christ, Tim J C Bruxner, Michael C Quinn,[...]. Nature 2016
8

Whole genomes redefine the mutational landscape of pancreatic cancer.
Nicola Waddell, Marina Pajic, Ann-Marie Patch, David K Chang, Karin S Kassahn, Peter Bailey, Amber L Johns, David Miller, Katia Nones, Kelly Quek,[...]. Nature 2015
8

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.
Prashanth Rawla, Tagore Sunkara, Vinaya Gaduputi. World J Oncol 2019
839
8

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao,[...]. J Clin Oncol 2013
433
8

Pancreatic cancer.
Jorg Kleeff, Murray Korc, Minoti Apte, Carlo La Vecchia, Colin D Johnson, Andrew V Biankin, Rachel E Neale, Margaret Tempero, David A Tuveson, Ralph H Hruban,[...]. Nat Rev Dis Primers 2016
896
8

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
7

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle, Stefan Post, Peter Neuhaus, Klaus Gellert, Jan Langrehr, Karsten Ridwelski, Harald Schramm, Joerg Fahlke, Carl Zuelke, Christof Burkart,[...]. JAMA 2007
7

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O'Reilly, David Cunningham, Jonathan Wadsley,[...]. Lancet 2017
7

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Mustafa Suker, Berend R Beumer, Eran Sadot, Lysiane Marthey, Jason E Faris, Eric A Mellon, Bassel F El-Rayes, Andrea Wang-Gillam, Jill Lacy, Peter J Hosein,[...]. Lancet Oncol 2016
508
7

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Paolo P Provenzano, Carlos Cuevas, Amy E Chang, Vikas K Goel, Daniel D Von Hoff, Sunil R Hingorani. Cancer Cell 2012
7

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.
Berna C Özdemir, Tsvetelina Pentcheva-Hoang, Julienne L Carstens, Xiaofeng Zheng, Chia-Chin Wu, Tyler R Simpson, Hanane Laklai, Hikaru Sugimoto, Christoph Kahlert, Sergey V Novitskiy,[...]. Cancer Cell 2014
7

Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Yoav Binenbaum, Shorook Na'ara, Ziv Gil. Drug Resist Updat 2015
205
7

PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Sharlene Gill, Yoo-Joung Ko, Christine Cripps, Annie Beaudoin, Sukhbinder Dhesy-Thind, Muhammad Zulfiqar, Pawel Zalewski, Thuan Do, Pablo Cano, Wendy Yin Han Lam,[...]. J Clin Oncol 2016
146
6

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Helmut Oettle, Hanno Riess, Jens M Stieler, Gerhard Heil, Ingo Schwaner, Jörg Seraphin, Martin Görner, Matthias Mölle, Tim F Greten, Volker Lakner,[...]. J Clin Oncol 2014
281
6

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
6

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
6

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
6

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Daniel D Von Hoff, Ramesh K Ramanathan, Mitesh J Borad, Daniel A Laheru, Lon S Smith, Tina E Wood, Ronald L Korn, Neil Desai, Vuong Trieu, Jose L Iglesias,[...]. J Clin Oncol 2011
768
6

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Eva Versteijne, Mustafa Suker, Karin Groothuis, Janine M Akkermans-Vogelaar, Marc G Besselink, Bert A Bonsing, Jeroen Buijsen, Olivier R Busch, Geert-Jan M Creemers, Ronald M van Dam,[...]. J Clin Oncol 2020
393
6

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
John P Neoptolemos, Deborah D Stocken, Claudio Bassi, Paula Ghaneh, David Cunningham, David Goldstein, Robert Padbury, Malcolm J Moore, Steven Gallinger, Christophe Mariette,[...]. JAMA 2010
924
6

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
6

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Philip A Philip, Jacqueline Benedetti, Christopher L Corless, Ralph Wong, Eileen M O'Reilly, Patrick J Flynn, Kendrith M Rowland, James N Atkins, Barry C Mirtsching, Saul E Rivkin,[...]. J Clin Oncol 2010
481
6

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
Michael J Pishvaian, Edik M Blais, Jonathan R Brody, Emily Lyons, Patricia DeArbeloa, Andrew Hendifar, Sam Mikhail, Vincent Chung, Vaibhav Sahai, Davendra P S Sohal,[...]. Lancet Oncol 2020
192
6

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
M Ducreux, A Sa Cuhna, C Caramella, A Hollebecque, P Burtin, D Goéré, T Seufferlein, K Haustermans, J L Van Laethem, T Conroy,[...]. Ann Oncol 2015
667
6

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Sunil R Hingorani, Lei Zheng, Andrea J Bullock, Tara E Seery, William P Harris, Darren S Sigal, Fadi Braiteh, Paul S Ritch, Mark M Zalupski, Nathan Bahary,[...]. J Clin Oncol 2018
264
6

Pancreatic Cancer: A Review.
Wungki Park, Akhil Chawla, Eileen M O'Reilly. JAMA 2021
141
6

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Daniel V T Catenacci, Melissa R Junttila, Theodore Karrison, Nathan Bahary, Margit N Horiba, Sreenivasa R Nattam, Robert Marsh, James Wallace, Mark Kozloff, Lakshmi Rajdev,[...]. J Clin Oncol 2015
332
6

Pancreatic adenocarcinoma.
David P Ryan, Theodore S Hong, Nabeel Bardeesy. N Engl J Med 2014
6

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Hong Jiang, Samarth Hegde, Brett L Knolhoff, Yu Zhu, John M Herndon, Melissa A Meyer, Timothy M Nywening, William G Hawkins, Irina M Shapiro, David T Weaver,[...]. Nat Med 2016
534
6

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Max M Wattenberg, Daniella Asch, Shun Yu, Peter J O'Dwyer, Susan M Domchek, Katherine L Nathanson, Mark A Rosen, Gregory L Beatty, Evan S Siegelman, Kim A Reiss. Br J Cancer 2020
82
6


Pancreatic cancer.
Audrey Vincent, Joseph Herman, Rich Schulick, Ralph H Hruban, Michael Goggins. Lancet 2011
5

Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
Andrew McGuigan, Paul Kelly, Richard C Turkington, Claire Jones, Helen G Coleman, R Stephen McCain. World J Gastroenterol 2018
644
5

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
David Goldstein, Robert Hassan El-Maraghi, Pascal Hammel, Volker Heinemann, Volker Kunzmann, Javier Sastre, Werner Scheithauer, Salvatore Siena, Josep Tabernero, Luis Teixeira,[...]. J Natl Cancer Inst 2015
384
5

Pancreatic cancer.
Manuel Hidalgo. N Engl J Med 2010
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.